Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers

Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers

Cytotoxic T lymphocyte (CTL)-based immunotherapies can induce tumor regressions by targeting HLA class I-bound tumor-associated peptides. Here, the authors identified a peptide derived from Vestigial-like 1 (VGLL1) as a shared, potentially therapeutic CTL target expressed by multiple cancer types.

Bibliographic Details
Main Authors: Sherille D. Bradley, Amjad H. Talukder, Ivy Lai, Rebecca Davis, Hector Alvarez, Herve Tiriac, Minying Zhang, Yulun Chiu, Brenda Melendez, Kyle R. Jackson, Arjun Katailiha, Heather M. Sonnemann, Fenge Li, Yaan Kang, Na Qiao, Bih-Fang Pan, Philip L. Lorenzi, Mark Hurd, Elizabeth A. Mittendorf, Christine B. Peterson, Milind Javle, Christopher Bristow, Michael Kim, David A. Tuveson, David Hawke, Scott Kopetz, Robert A. Wolff, Patrick Hwu, Anirban Maitra, Jason Roszik, Cassian Yee, Gregory Lizée
Format: Article
Language:English
Published: Nature Publishing Group 2020-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-19141-w

Internet

https://doi.org/10.1038/s41467-020-19141-w

Similar Items